Theseus Pharmaceuticals, Inc. (THRX)
Feb 14, 2024 - THRX was delisted (reason: acquired by Concentra Biosciences)
4.060
0.00 (0.00%)
Last trade price

Theseus Pharmaceuticals Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Year 2022202120202019
Net Income
-50.61-27.31-12-7.18
Depreciation & Amortization
0.44000
Share-Based Compensation
11.414.361.050.32
Other Operating Activities
5.81-4.256.092.06
Operating Cash Flow
-32.95-27.19-4.85-4.81
Capital Expenditures
-0.46000
Change in Investments
-116.84000
Investing Cash Flow
-117.29000
Share Issuance / Repurchase
0.18163.8900
Other Financing Activities
-99.8911.992.99
Financing Cash Flow
0.18263.7811.992.99
Net Cash Flow
-150.06236.587.14-1.81
Free Cash Flow
-33.4-27.19-4.85-4.81
Free Cash Flow Per Share
-0.87-2.82-8.54-30.24
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).